HOWL
Werewolf·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 3
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
Significant Revenue Decline
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About HOWL
Werewolf Therapeutics, Inc.
An innovative biopharmaceutical company that develops engineered therapeutics to stimulate the body's immne system for the treatment of cancer
200 Talcott Ave, 2nd Floor, Watertown, Massachusetts 02472
--
Werewolf Therapeutics, Inc., was incorporated under the laws of the State of Delaware on October 19, 2017. The company is an innovative biopharmaceutical company that develops therapies designed to stimulate the body's immune system to treat cancer. The company is utilizing the company's proprietary PREDATOR platform to design conditionally activated molecules that stimulate adaptive immunity and innate immunity to address the limitations of traditional pro-inflammatory immunotherapies.
Company Financials
EPS
HOWL has released its 2025 Q3 earnings. EPS was reported at -0.36, versus the expected -0.38, beating expectations. The chart below visualizes how HOWL has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
